- Home
- Equipment
- united kingdom
- preclinical efficacy data
Refine by
Preclinical Efficacy Data Equipment Supplied In United Kingdom
6 equipment items found
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. Preclinical data ...
Manufactured by:Sequana Medical NV based inSint-Denijs Westrem, BELGIUM
Direct Sodium Removal (DSR®) therapy is Sequana Medical’s novel and proprietary approach under development for the management of fluid overload due to heart failure. The sodium concentration in patients with fluid overload is in balance but there is too much sodium and too much fluid in the body. Sequana Medical’s approach is to remove excess sodium in patients with ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats including, but not limited to, ...
by:Procarta Biosystems Ltd based inNorwich, UNITED KINGDOM
Proprietary nanoparticles deliver an oligonucleotide inside the bacterial pathogen. The oligonucleotide acts as a Transcription Factor Decoy (TFD): it contains the binding site of a transcription factor that controls a large set of genes required for the survival of the bacterium. The TFD acts as a competitive inhibitor to prevent these genes being turned on and so prevents growth and treats the ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly ...
Manufactured by:CN Bio based inCambridge, UNITED KINGDOM
Generate human-specific pre-clinical safety and efficacy data with pioneering PhysioMimix single- and multi-organ-on-a-chip ...